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Invariant natural killer T (iNKT) cells recognize activating self and microbial 2 
lipids presented by CD1d.  CD1d can also bind non-activating lipids, such as 3 
sphingomyelin. We hypothesized that these serve as endogenous regulators and 4 
investigated humans and mice deficient in acid sphingomyelinase (ASM), an 5 
enzyme that degrades sphingomyelin. We show that ASM absence in mice leads 6 
to diminished CD1d-restricted antigen presentation and iNKT cell selection 7 
resulting in decreased iNKT cell levels and resistance to iNKT cell-mediated 8 
inflammatory conditions. Defective antigen presentation and decreased iNKT 9 
cells are also observed in ASM-deficient humans with Niemann-Pick Disease and 10 
ASM activity in healthy humans correlates with iNKT cell phenotype. 11 
Pharmacological ASM administration facilitates antigen presentation and 12 
restores the levels of iNKT cells in Asm–/– mice. Together, these results 13 
demonstrate that control of non-agonistic CD1d-associated lipids is critical for 14 
iNKT cell development and function in vivo and represent a tight link between 15 
cellular sphingolipid metabolism and immunity.  16 
 17 




Invariant natural killer T (iNKT) cells are an important lymphocyte population that 1 
serves in sensing self and microbial lipids presented by the major histocompatibility 2 
complex (MHC) class I-like glycoprotein CD1d1. In response to these antigens, iNKT 3 
cells rapidly release large arrays of mediators, making them powerful and early 4 
modulators of immune pathways2. The self-reactivity of iNKT cells is also critical for 5 
their development in the thymus3. Here, iNKT cells are positively selected by CD1d-6 
bearing thymocytes4. While there have been significant efforts to identify CD1d-7 
binding, iNKT cell activating lipids (i.e. lipid antigens5), iNKT cell activation is also 8 
amenable to negative regulation by CD1d-associated lipids which do not stimulate the 9 
iNKT T cell receptor (TCR). As such, iNKT cell activation is anticipated to be 10 
influenced by the balance of CD1d-associated antigenic and non-antigenic lipids. 11 
However, little is known about the functional relevance of non-antigenic lipids that 12 
potentially impede CD1d-restricted iNKT cell activation. Sphingolipids, which are 13 
abundantly present in the cell membrane6, are a major class of CD1d-associated 14 
lipids7,8. Sphingomyelin, a dominant sphingolipid in mammals, has been reported to 15 
be a non-stimulatory CD1d-associated lipid in vitro9, leading us to hypothesize that it 16 
may regulate CD1d access to potentially agonistic lipids.  17 
 18 
Sphingomyelin is degraded by sphingomyelinases into ceramide and 19 
phosphorylcholine10. In lysosomes, one of the sites where the exchange and loading 20 
of lipids onto CD1d takes place11, acid sphingomyelinase (ASM) is the primary 21 
enzyme responsible for sphingomyelin degradation12,13. In light of the non-22 
stimulatory nature of sphingomyelin in vitro9, we sought to understand the 23 
consequences of sphingomyelin accumulation on iNKT cell function. To do so, we 24 




sphingomyelin and a clinical phenotype resembling ASM-deficiency in humans, 1 
known as Niemann-Pick Disease Types A and B (NPD-A and –B), where type A is 2 
the more severe form of disease debuting during infancy. We demonstrate that control 3 
of the cellular abundance of sphingomyelin by ASM regulates the presentation of 4 
endogenous and exogenous lipid antigens by CD1d in thymocytes and dendritic cells 5 
(DC) and thus the abundance and activation of iNKT cells. In the absence of ASM in 6 
mice, sphingomyelin levels increase in hematopoietic cells resulting in decreased 7 
CD1d-restricted antigen presentation, impaired iNKT cell development in the thymus 8 
and reduced abundance and activation of iNKT cells – defects that are reversed by the 9 
transfer of wildtype bone-marrow or administration of recombinant human (rh)ASM. 10 
These observations are extensible to humans with or without NPD and establish 11 
ASM, through its control of sphingomyelin levels, as an important regulator of iNKT 12 
cells with potential therapeutic implications.  13 
 14 
RESULTS 15 
ASM is active in the hematopoietic system and required for iNKT cell 16 
development 17 
Although it is well established that ASM is expressed in tissues where the clinical 18 
phenotypes of NPD-A and –B are most prominent, such as the liver and brain as well 19 
as in some hematopoietic cells, such as macrophages15, little is known about its 20 
function in the immune system. Therefore, we first investigated ASM activity and 21 
found it to be demonstrable in a variety of parenchymal (colon, liver) and 22 
hematopoietic (spleen, thymus and DC) cells with the highest levels in DCs (Fig. 1a), 23 
a critical CD1d-expressing antigen presenting cell (APC) in the periphery16. 24 




Supplementary Fig. 1), revealed a dramatic reduction of iNKT cells in the thymus, 1 
liver and spleen of adult Asm–/– mice (Fig. 1b, 1c and Supplementary Fig. 2a). This 2 
was associated with a perturbation in the distribution of the few remaining iNKTs, as 3 
shown by decreased relative levels of iNKT cells which expressed CD4 and a relative 4 
enrichment in the CD4–CD8– (double negative, DN) iNKT cell fraction in the 5 
periphery (spleen and liver) (Supplementary Fig. 2b). The reduction in iNKT cell 6 
abundance was also associated with a decrease in absolute iNKT cell numbers (Fig. 7 
1d). Furthermore, when PBS57-loaded CD1d tetramer positive cells (i.e. iNKT cells) 8 
were excluded there were no changes in the relative abundance of tetramer-negative 9 
thymic T cells (Supplementary Fig. 3a) or alterations in the distribution of CD4+, 10 
CD8+, DN or CD4+CD8+ (double-positive, DP) thymocytes (Supplementary Fig. 3b). 11 
In the periphery, tetramer-negative T cells were unaltered in relative abundance in the 12 
livers of Asm–/– mice and slightly reduced in the spleen of these mice (Supplementary 13 
Fig. 3a) in association with minor changes in proportion of CD4+, CD8+ and DN cells 14 
(Supplementary Fig. 3b). We also did not observe changes in the relative abundance 15 
of gd T cells, another type of unconventional T cell, and T regulatory (Treg) cells when 16 
tetramer positive cells were excluded from the analysis (Supplementary Fig. 3c). To 17 
rule out that the reduction in iNKT cells was secondary to a general disturbance of 18 
lysosomal function, we investigated mice just after weaning at the age of 2 weeks, 19 
when the accumulation of sphingomyelin in parenchymal tissues is known to be 20 
minimal14. In these young mice, we also observed a reduction in iNKT cells (Fig. 1e). 21 
These studies demonstrate that ASM is functionally present in immune tissues and 22 
deficiency is associated with a specific alteration of iNKT cell homeostasis.  23 
 24 




To determine whether ASM-deficiency affects iNKT cell function in vivo, we 1 
examined the responses of Asm–/– mice in three different iNKT cell-dependent disease 2 
models. First, systemic a-GalCer administration, a model of iNKT cell-mediated 3 
hepatitis, resulted in reduced serum levels of alanine transaminase (ALT) and 4 
cytokines including interleukin (IL)-4 and interferon (IFN)-γ in Asm–/– mice compared 5 
to wild-type mice (Fig. 2a). Second, we observed that delayed type hypersensitivity 6 
(DTH) induced by oxazolone, a model for skin allergy that is dependent on iNKT cell 7 
activation17 was reduced in Asm–/– mice, as defined by weight loss after skin 8 
sensitization (Fig. 2b) and ear swelling following oxazolone re-challenge (Fig. 2c). 9 
Lastly, we examined concanavalin A (ConA) hepatitis, a model of hepatic injury 10 
driven by direct (CD1d-independent) activation of iNKT cells18. In this model, tissue 11 
damage (Fig. 2d-e) and damage-associated elevations of serum transaminases (Fig. 12 
2f) were dramatically reduced in Asm–/– mice, which was accompanied by a reduction 13 
in the expression of iNKT cell-associated cytokines such as IL-4 after 6 hours and 14 
IFN-γ after 24 hours in the serum (Fig. 2f). Such diminished in vivo responses to 15 
a-GalCer, oxazolone and ConA in Asm–/– mice are consistent with the decreased 16 
levels of iNKT cells and/or impaired presentation of agonistic CD1d-restricted 17 
antigens. Together, these models document the importance of ASM in regulating 18 
iNKT cell-dependent inflammation.  19 
 20 
ASM deficiency leads to altered lipid antigen presentation and thymic iNKT cell 21 
selection 22 
We hypothesized that the reduction in iNKT cells observed in Asm–/– mice was due to 23 
reduced presentation of CD1d-restricted antigens involved in positive selection of 24 




cells, which are positively selected by cortical thymic epithelial cells, iNKT cells are 1 
selected by CD1d-expressing thymocytes4. We observed that, although CD1d 2 
expression was unaffected by ASM-deficiency in young mice and only slightly 3 
reduced in the thymus of adult mice (Supplementary Fig. 4), thymocytes from both 4 
adult and young (2 weeks old) Asm–/– mice compared to wildtype thymocytes led to 5 
reduced IL-2 release by co-cultured iNKT hybridomas in response to CD1d-restricted 6 
presentation of endogenous (self) and exogenous (a-GalCer) antigens (Fig. 3a). Of 7 
note, similar cell surface expression of CD1d in young Asm–/– and wildtype mice 8 
suggests that defects in CD1d-restricted antigen presentation in the absence of ASM 9 
are not an indirect consequence of altered CD1d trafficking as the latter typically 10 
affects CD1d cell surface expression19,20.  Further, the iNKT hybridomas used are 11 
ASM-proficient, which rules out iNKT cell intrinsic defects due to the lack of ASM 12 
as the cause of reduced activation. Inhibition with 19G11, a monoclonal antibody 13 
directed against CD1d, confirmed that iNKT cell activation in these assays was 14 
CD1d-dependent (Supplementary Fig. 5a).  15 
 16 
Given the dramatic reduction iNKT cells in Asm–/– mice and the defects of Asm–/– 17 
thymocytes in CD1d-restricted antigen presentation (Fig. 3a), we investigated whether 18 
ASM deficiency affects thymic development of iNKT cells. To this end, we 19 
characterized thymic iNKT-cell development4. As expected from the reduction in 20 
thymic iNKT cells in Asm–/– mice (Fig. 1c-d), ASM deficiency was associated with 21 
dramatically reduced absolute numbers of iNKT cells at stages 1, 2 and 3 of thymic 22 
development (Fig. 3b, left). Within the small population of thymic iNKT cells in Asm–23 




compared to wildtype mice (Fig. 3b, right). These results suggest a major bottle-neck 1 
at the earliest stages of iNKT development in the thymus when ASM is absent. 2 
 3 
To rule out that these developmental differences were due to an intrinsic defect in 4 
iNKT cells in Asm–/– mice rather than an abnormality in antigen presentation resulting 5 
in altered iNKT cell positive selection, we generated mixed bone marrow chimeras in 6 
which irradiated Ja18–/– recipients received bone marrow from Ja18–/– mice, which 7 
are ASM sufficient and express CD1d but do not give rise to iNKT cells due to 8 
deficiency of the invariant TCR Ja segment21, mixed 1:1 with bone marrow from 9 
either Asm–/– or wildtype mice. In this experiment, functional CD1d was provided by 10 
Ja18–/– thymocytes which should allow for unimpaired iNKT cell development of the 11 
precursor cells in the Asm–/– bone marrow which are the only source of iNKT cells in 12 
this experiment. In line with this hypothesis, iNKT cells derived from Asm–/– 13 
compared to wildtype bone marrow were observed at similar abundance in the 14 
thymus, spleen and liver (Fig. 3c). These studies ruled out a cell-intrinsic defect in 15 
iNKT cells in the developing thymus of Asm–/– mice. Further, reconstitution of 16 
irradiated CD45.2+ Asm–/– mice with bone marrow from wildtype ASM-expressing 17 
CD45.1+ mice restored iNKT cells (Fig. 3d and e). These studies demonstrate that 18 
iNKT cell defects in Asm–/– mice arise from the bone marrow-derived radiosensitive 19 
compartment. Control experiments with irradiation of Asm–/– mice followed by 20 
transfer of Asm–/– bone marrow were not associated with an increase in the abundance 21 
of iNKT cells (Supplementary Fig. 5b). 22 
 23 
Similar to thymocytes, CD11c+ DCs from spleens of young and adult Asm–/– mice 24 




hybridoma 14S.6 and the iNKT cell hybridoma 24.822 (Fig. 3f). Additionally, we 1 
observed decreased presentation of endogenous and exogenous (α-GalCer) lipid 2 
antigens to the 24.7 and DN32.D3 iNKT cell hybridomas in comparison to DCs from 3 
wildtype mice (Fig. 3g). The activation of iNKT cells was CD1d-restricted and 4 
abolished by antibody-mediated blockade of CD1d (Supplementary Fig. 5c). By 5 
direct staining using a monoclonal antibody recognizing the complex of α-GalCer 6 
bound to CD1d on the cell surface, it was evident that reduced iNKT cell activation 7 
resulted from reduced loading of CD1d with α-GalCer (Fig. 3h). Finally, MHC class 8 
II-restricted antigen presentation of ovalbumin by DCs, which requires lysosomal 9 
processing of the model antigen ovalbumin, to T cells from OT-II mice23, was 10 
unperturbed in Asm–/– mice, thus excluding general defects in lysosomal antigen 11 
processing and presentation of antigens to T cells (Fig. 3i). Together, these data 12 
demonstrate that ASM-deficiency limits the ability of thymocytes and DCs to load 13 
and present CD1d-associated antigens resulting in defects in thymic development and 14 
maturation of iNKT cells.  15 
 16 
ASM deficiency in humans is associated with reduced abundance of iNKT cells 17 
and an altered iNKT cell phenotype 18 
To extend these studies to humans, we investigated whether a similar defect in CD1d-19 
restricted antigen presentation can be detected in patients with NPD-A and -B who are 20 
deficient in ASM. To this end, we used lentiviral transduction to introduce human 21 
CD1d into Epstein-Barr virus (EBV)-transformed B cells from an NPD type B patient 22 
and three healthy controls (Supplementary Fig. 6a). While CD1d expression in NPD 23 
lymphoblasts was within the range observed for controls (Supplementary Fig. 6a), the 24 




presentation of a-GalCer to the iNKT hybridoma 58ab24 compared to similarly 1 
transfected control lymphoblasts (Fig. 4a). Given reduced iNKT cell numbers in Asm–2 
/– mice, we analyzed the abundance of iNKT cell levels in peripheral blood of NPD-A 3 
and –B patients. While iNKT cell numbers showed variation in healthy controls in 4 
line with previous observations25, iNKT cell frequencies in NPD-A and -B patients 5 
were significantly decreased and at the lower end of those observed in controls (Fig. 6 
4b-c and Supplementary Table 1). The median relative abundance of iNKT cells 7 
among NPD-A and -B patients was 0.014% (Interquartile range (IQR) 0.012%-8 
0.029%) compared to 0.086% (IQR 0.037%-0.18%) among the control subjects 9 
(P=0.0004). In addition, the phenotype of the residual iNKT cells in NPD patients 10 
differed from controls as shown by a dramatically altered CD4+/CD8+ iNKT cell ratio 11 
and reduced expression of the maturation marker CD16126, which is acquired through 12 
interactions with CD1d in the periphery4 (Supplementary Fig. 6b). This reduction in 13 
iNKT cells in human NPD subjects is in marked contrast to observations in Gaucher’s 14 
disease27, Fabry’s disease28 and Niemann-Pick disease Type C29, all of which 15 
represent sphingolipid-dependent lysosomal storage diseases, wherein iNKT cell 16 
levels are not affected. In contrast to iNKT cells, no alterations were detected in the 17 
abundance of conventional T cells or their CD4+ and CD8+ subpopulations (Fig. 4d 18 
and Supplementary Fig. 6c). In conclusion, the iNKT cell defects observed in NPD 19 
patients suggest a role of ASM in the regulation of human iNKT cell development, in 20 
line with the observations made in Asm–/– mice. The absence of defects in 21 
conventional T cells in NPD patients further suggests that such alterations are specific 22 
to iNKT cells and that they do not result from general defects in lysosomal antigen 23 




(Fig. 3i) and unaffected frequencies of conventional T cells (Supplementary Fig. 3a) 1 
in Asm–/– mice.  2 
 3 
We also evaluated a potential correlation between ASM activity and iNKT cell 4 
abundance and function among healthy humans. To this end, we determined ASM 5 
activity in peripheral blood mononuclear cells (PBMC) and correlated it with 6 
peripheral iNKT cell frequency and the iNKT cell phenotype. While we did not 7 
observe a correlation between ASM activity in PBMCs and the abundance of iNKT 8 
cells, ASM activity was variable and positively correlated with the expression of 9 
CD161 and the relative proportion of iNKT cells expressing CD8 (Fig. 4e). These 10 
results suggest that ASM activity regulates CD1d and NKT cells in the periphery 11 
and/or the thymus in healthy human subjects under physiological conditions. 12 
 13 
ASM deficiency leads to early accumulation of sphingomyelin, which competes 14 
with agonistic lipids for binding to CD1d 15 
Our results so far demonstrated that deficiency in ASM is associated with impaired 16 
presentation of CD1d-associated antigens leading to defects in the positive selection 17 
of iNKT cells. We therefore analyzed whether changes in the lipidome contribute to 18 
the observed defects. To this end, we first examined the lipid content of thymi and 19 
livers of 2-week old wildtype and Asm–/– mice using mass spectrometry. The analysis 20 
of the thymus revealed an increase in sphingomyelin and DH-sphingomyelin levels 21 
with C24:1 and C16:0 being the most abundant species detected (Fig. 5a), while the 22 
levels of ceramides and DH-ceramides, the breakdown products of sphingomyelin and 23 
DH-sphingomyelin, were unaffected (Fig. 5b). In comparison, an analysis of total 24 




abundance in Asm–/– relative to wildtype mice (Supplementary Fig. 7). We therefore 1 
investigated whether the species of sphingomyelin increased in Asm–/– thymi could 2 
interfere with CD1d-mediated antigen presentation. To exclude lipid effects on the 3 
APCs themselves, we used an APC-free assay with platebound CD1d9 where 4 
sphingomyelin and α-GalCer directly compete for binding to CD1d. In addition, we 5 
used sphingomyelin concentrations that were within the range of the molar 6 
concentrations of sphingomyelin observed in thymocytes, calculated based on the 7 
average size of a thymocyte30. We observed that sphingomyelin 24:1 inhibited the 8 
ability of a-GalCer to stimulate the DN32.D3 hybridoma in response to plate bound 9 
CD1d, while sphingomyelin 16:0 species possessed a detectable albeit less 10 
pronounced inhibitory effect (Fig. 5c). The other sphingomyelin species that were 11 
increased in Asm–/– mice made up only a small fraction compared to the levels of 24:1 12 
and 16:0 sphingomyelin. Nevertheless, we tested the effects of the next most elevated 13 
species and observed that 24:0 and 18:0 sphingomyelin elicited similar effects in 14 
blocking a-GalCer presentation (Fig. 5d). Direct activation of the DN32.D3 15 
hybridoma with plate bound anti-CD3 was not influenced by the inhibitory 16 
sphingomyelin species indicating that sphingomyelin did not directly affect iNKT cell 17 
function (Supplementary Fig. 8a). Furthermore, we confirmed, using the plate-bound 18 
CD1d assay, that ASM does not directly facilitate the loading of lipids onto CD1d 19 
(Supplementary Fig. 8b). These studies indicate that ASM-deficiency is associated 20 
with accumulation of sphingomyelin species that compete with agonistic CD1d-21 
binding lipids, thus limiting their ability to stimulate iNKT cells. Since iNKT cells are 22 
selected by antigens processed in the endolysosomal pathway20,31 and presented by 23 
other thymocytes, we developed a novel technique for defining the lipid content of the 24 




thymocytes was confirmed by the enrichment of lysosomal markers (Lamp1, Lamp2 1 
and CtsD), but not markers for mitochondria (CoxIV), early endosomes (Rab5) nuclei 2 
(HisH3) or cytosol (GAPDH, tubulin) as determined by Western blot (magnetic 3 
fraction in Fig. 6a) and electron microscopy (Fig. 6b). Lipidomic analysis of the 4 
purified lysosome fractions demonstrated an increased ratio of the sphingomyelin 5 
species shown to be inhibitory for CD1d-restricted antigen presentation (Fig. 5c and 6 
d), relative to the total level of ceramide in Asm–/– compared to wildtype thymocytes 7 
of 2-week (Fig. 6c), 10-week (Fig. 6d) and 20-week old mice (Fig. 6e). It is notable 8 
that significantly elevated ratios of sphingomyelin species were already observed in 9 
the lysosomes of thymocytes of 2-week old mice, which is consistent with the iNKT 10 
cell defects observed at these early stages of development and thus long before other 11 
features of ASM deficiency arise. 12 
 13 
Sphingomyelin can displace agonistic lipids from CD1d 14 
Our results suggested that ASM deficiency lead to early accumulation of 15 
sphingomyelin, which competes as a non-agonistic lipid with agonistic lipids for 16 
binding to CD1d. This leads to interference with CD1d-restricted positive selection of 17 
iNKT cells in the thymus and with CD1d-dependent maturation of iNKT cells in the 18 
periphery. We therefore addressed whether sphingomyelin, in addition to its ability to 19 
compete with agonistic lipids for binding to CD1d (Fig. 5c-d), can also displace 20 
agonistic lipids that are already bound to CD1d. To this end, recombinant CD1d was 21 
loaded with sulfatide (SLF), a negatively charged agonistic lipid for non-invariant 22 
NKT cells32,33, and incubated with increasing concentrations of sphingomyelin to 23 
address whether sphingomyelin can actively displace SLF. Indeed, successful 24 




electrophoresis by a band shift to the 0 position. Even at a 1:1 (sphingomyelin:SLF) 1 
molar ratio, sphingomyelin replaced approximately 50% of the bound sulfatide 2 
similar to that observed with the agonistic lipid a-GalCer (Fig. 7a). When we first 3 
loaded sphingomyelin or a-GalCer onto murine CD1d and then added sulfatide, we 4 
observed less replacement of a-GalCer compared to sphingomyelin (Fig. 7a). 5 
However, it is anticipated that these differences in affinity to CD1d are outweighed in 6 
vivo by the massive increase in molar abundance of sphingomyelin leading to an 7 
excess of lipids that bind to CD1d but do not provide activating signals to iNKT cells. 8 
Together, these data demonstrate that sphingomyelin can directly compete with, and 9 
replace, agonistic lipids from CD1d, consistent with its ability to interfere with CD1d-10 
restricted antigen presentation.  11 
 12 
CD1d-sphingomyelin structure 13 
To examine the molecular basis of the aforementioned observations we determined 14 
the mouse CD1d-sphingomyelin (CD1d-SM) structure to a resolution of 1.95 Å 15 
(Table 1). A well-ordered electron density for the lipid was observed throughout the 16 
structure, with the exception of the choline group, which appeared to be flexible, 17 
since it did not form considerable contacts with CD1d (Fig. 7b-e, PDB structure ID: 18 
6CYW). The C24:1 acyl chain of sphingomyelin was contained in the larger A’ 19 
pocket, while the sphingosine was inserted into the F’ pocket, similar to the binding 20 
of other glycosphingolipids such as sulfatide or a-GalCer34,35. In contrast to the 21 
binding of a-GalCer34, sphingomyelin was observed to form fewer H-bond 22 
interactions with CD1d, of which the lack of an interaction with D153 was especially 23 
noticeable. In contrast, the phosphate group formed a novel contact with S76 and a 24 




antigen for iNKT cells, since sphingomyelin lacks the typical a-anomerically linked 1 
hexose sugar that is the hallmark of strong iNKT cell antigens. The resolved structure 2 
agrees with the observation that once a-GalCer is bound to CD1d, it is not easily 3 
outcompeted by sulfatide, while sphingomyelin appears to interact less tightly with 4 
CD1d, supporting the notion that sulfatide can outcompete sphingomyelin more 5 
easily. However, the binding assay also revealed that CD1d bound lipids can be 6 
replaced against other lipids in a dose-dependent manner. This phenomenon is 7 
drastically different to that of peptide binding to conventional MHC I molecules, 8 
where it is difficult to replace a peptide once its bound36. 9 
 10 
Treatment with recombinant human ASM can restore iNKT-levels 11 
Our results raised the question of whether restoration of ASM in Asm–/– mice could 12 
reverse sphingomyelin-dependent inhibition of CD1d-restricted antigen presentation 13 
or even augment presentation by wildtype cells. As in vivo administration of 14 
recombinant human ASM (rhASM)37 has been shown to reverse the visceral lipid 15 
defect in Asm–/– mice38 and is under development as treatment for Type B NPD, we 16 
reasoned that in vivo injection of rhASM may enhance CD1d-restricted antigen 17 
presentation and restoration of iNKT cell development. Importantly, it has been 18 
shown that rhASM is taken up into lysosomes37, where CD1d localizes and lipid 19 
exchange occurs39. Indeed, one day after rhASM administration into Asm–/– (Fig. 8a) 20 
or wildtype mice (Fig. 8b), spleen DCs exhibited increased a-GalCer-induced iNKT 21 
cell activation compared to vehicle-treated mice. Of note, the ability of rhASM to 22 
increase iNKT cell activation by wildtype DCs suggests that ASM serves as a tunable 23 
factor in determining the CD1d-dependent antigen presentation capacity of DCs under 24 




could reverse the reduction in iNKT cell levels in Asm–/– mice. Following 2 weeks of 1 
rhASM treatment, ASM activity was significantly increased in the thymi and livers of 2 
Asm–/– treated mice (Fig. 8c) and thymic sphingomyelin abundance was reduced to 3 
that found in wildtype mice (Fig. 8d). Moreover, this was associated with an increase 4 
in iNKT cells (Fig. 8e and f). Together, these results demonstrate that rhASM 5 
enhances CD1d-restricted antigen presentation in wildtype and Asm–/– DCs and can 6 
partially restore the iNKT cell defect observed in Asm–/– mice. 7 
 8 
DISCUSSION 9 
iNKT cells are a potent subset of T cells, whose activation requires tight control to 10 
prevent overt autoimmunity8. While previous work has focused on the identification 11 
of CD1d-associated lipids that activate iNKT cells (agonistic lipids), lipidomic studies 12 
have revealed that the vast majority of CD1d-associated lipids are non-agonistic self-13 
lipids, derived from abundant cellular sphingolipids and glycerophospholipids40. This 14 
raises the question of whether the abundance of such non-agonistic CD1d-associated 15 
lipids is critical for control of iNKT cell development, CD1d-restricted iNKT cell 16 
activation and iNKT cell-mediated inflammation. Here, we have addressed this 17 
question through the study of ASM, an enzyme critical for control of the abundance 18 
of sphingomyelin, a major CD1d-associated lipid which does not activate iNKT cells. 19 
Our results demonstrate that ASM, through control of the abundance of 20 
sphingomyelin, regulates the balance between activating and non-activating CD1d-21 
associated lipids and controls iNKT activation and development.  22 
 23 
These studies highlight and focus attention on the important role played by inhibitory 24 




to exogenously derived inhibitory sphingolipids provided by the commensal 1 
microbiota41, the host employs endogenous strategies to serve a similar purpose.  2 
The accumulation of sphingomyelin in Asm–/– mice was associated with diminished 3 
positive selection of iNKT cells in the thymus and altered maturation of iNKT cells in 4 
the thymus and the periphery4. This deficiency in iNKT cells also translated into 5 
altered responses in iNKT mediated disease models. Defects in the CD1d-iNKT axis 6 
observed in Asm–/– mice were paralleled by iNKT cell defects in NPD-A and B 7 
patients. These findings contrast patients with NPD-C, a disease sharing neurological 8 
phenotype but with a different molecular basis42, that have a normal distribution of 9 
iNKT cells29.  10 
 11 
Given the critical role of iNKT cells in antimicrobial immunity against common 12 
respiratory pathogens such as Pneumococcus and Pseudomonas spp. 43,44, iNKT cell 13 
defects are anticipated to contribute to susceptibility of NPD-A and NPD-B patients 14 
to pneumonia, which represents the most common cause of death in these patients45. 15 
However, the relevance of our data extends far beyond individuals with NPD-A and 16 
NPD-B. As such, the correlation between ASM activity and the iNKT cell phenotype 17 
in healthy individuals, as well as the promotion of CD1d-restricted antigen 18 
presentation by rhASM in wildtype mice suggests that ASM functions as a major 19 
regulator of iNKT cell development and function under constitutive conditions in 20 
normal hosts. Our results may also contribute to the understanding of the variability 21 
of iNKT cell levels and subsets in humans25. These observations likely apply in a 22 
similar manner to other major cellular lipids that associate with CD1d and fail to 23 
activate iNKT cells. As such, our findings suggest that iNKT cell development and 24 




broad implications for common immuno-metabolic diseases, such as non-alcoholic 1 
steatohepatitis, in which inflammation and tissue destruction is mediated by iNKT 2 
cells, and in which changes in lipid metabolism may indeed act as primary drivers of 3 
pathogenic iNKT cell activation through alterations in the balance between iNKT cell 4 
activating and non-activating lipids. As such, conditions that regulate ASM levels in 5 
immune cells may have important effects on iNKT cell function2. 6 
 7 
In conclusion, our studies pinpoint sphingomyelin as a lipid species that 8 
endogenously regulates CD1d-restricted antigen presentation by thymocytes and 9 
peripheral activation of iNKT cells in response to endogenous, as well as exogenous, 10 
stimulatory antigens. Further, we demonstrate that ASM, an enzyme localized in the 11 
lysosome, plays a critical role in regulating the levels of this important inhibitory 12 
lipid. In addition, our studies further suggest that these pathways are amenable to 13 
therapeutic manipulation not only in humans with lipid storage diseases46, but also in 14 
circumstances wherein ASM supplementation (or blockade) may aid in promoting 15 
CD1d-restricted responses that are beneficial in the treatment of infectious diseases, 16 
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FIGURE LEGENDS 1 
 2 
Figure 1. Acid sphingomyelinase deficient mice have a reduced number of iNKT 3 
cells. (a) ASM activity was measured in tissues from WT mice (n=4) using a 4 
colorimetric assay in tissue lysates generated by repeated freeze/thaw cycles from the 5 
indicated tissues. The results are representative of two independent experiments. (b) 6 
Representative flow cytometry of lymphocytes from spleens in WT and Asm–/– mice 7 
visualizing the number of iNKT cells as defined by a PBS57-loaded CD1d tetramer 8 
and CD3. (c) Percentages of iNKT cells among lymphocytes in thymus, spleen and 9 
liver of age and gender matched WT (n=5) and Asm–/– (n=4) mice defined by PBS57-10 
loaded CD1d tetramer and CD3 positivity. The results are representative of three 11 
independent experiments. (d) Absolute numbers of iNKT cells in thymus, spleen and 12 
liver of age and gender matched WT (n=5) and Asm–/– (n=5) mice defined by PBS57-13 
loaded CD1d tetramer and TCRb. The results are representative of three independent 14 
experiments. (e) Representative flow cytometry of lymphocytes from spleens in WT 15 
and Asm–/– mice at 2 weeks of age, visualizing the number of iNKT cells as defined by 16 
a PBS57-loaded CD1d tetramer and CD3. In all panels the mean values are shown 17 
with the error bars representing the SEM. P-values were calculated by a two-sided t-18 
test. *P<0.001, **P<0.0001 19 
 20 
 21 
Figure 2. NKT mediated disease models are affected by ASM deficiency. (a) Age and 22 
gender matched WT and Asm–/– mice were injected with 2 µg α-galactosylceramide 23 
i.p. Cytokine levels were determined in serum 4 and 24h after injection and ALT 24 
levels in serum 24h after the injections. Results are representative of three 25 




the skin at day 0. The mice were followed daily with weight measurements and the 1 
values reflect the weight relative to the starting weight. Results are representative of 2 
three independent experiments. (c) Five days after the skin sensitization the mice 3 
received a re-challenge by application of oxazolone to the ear. Ear swelling was 4 
measured by a sensitive micrometer and the lines indicate the increase in ear 5 
thickness. (d) Quantification of necrotic areas in WT and Asm–/– mice injected with 6 
concanavalin A. The results represent pooled results from three independent 7 
experiments. (e) Representative H&E stained tissue sections from WT and Asm–/– 8 
mice 24h after injection with concanavalin A. The black bar indicates 200µm. Results 9 
are representative of three independent experiments. (f) Age and gender matched WT 10 
and Asm–/– mice were injected with concanavalin A. Cytokine and ALT levels were 11 
determined in serum 6 and 24h after injection. The results represent pooled results 12 
from three independent experiments. In all panels the mean values are shown with the 13 
error bars representing the SEM. P-values were calculated by two-sided t-test (panel 14 
a), 2-way ANOVA (panel b and c) or the two-sided Mann-Whitney test (panel d and 15 




Figure 3. Lipid antigen presentation by thymocytes and DCs from ASM deficient 20 
mice is reduced and bone-marrow transfer restores iNKT cell levels in Asm–/– mice. 21 
(a) Thymocytes were incubated with α-galactosylceramide for 4h or left untreated, 22 
followed by addition of the indicated NKT hybridomas. Thymocytes from both young 23 
(2-week old) and adult Asm–/– mice were used as indicated. (b) The graphs show 24 
absolute (left) and relative (right) numbers of iNKT cells in different thymic 25 
developmental stages in Asm–/– mice and WT mice. Stage 1 was defined as 26 




CD24loCD44hiNK1.1hi. The results are representative of two independent 1 
experiments. (c,d,e) Bone-marrow chimeras were made by mixing Ja18–/– and WT 2 
(n=5) or Asm–/– (n=8) bone-marrow transferred to irradiated Ja18–/– recipients (c) or 3 
by transfer of WT CD45.1+ bone-marrow to Asm–/– mice (n=7) that was compared to 4 
non-irradiated Asm–/– mice not receiving bone-marrow (n=6)  (d,e). The graphs 5 
demonstrate the percentage of CD1d-PBS57 tetramer positive cells among TCRβ 6 
positive cells (iNKT cells) three months after bone-marrow transfer. In panel c the 7 
results are representative of two independent experiments while in panel e the results 8 
represent pooled results from three independent experiments. The dot plots in panel d 9 
show representative plots from the livers of a non-irradiated Asm–/– mouse not 10 
receiving bone-marrow and an Asm–/– mouse receiving WT bone-marrow. (f,g) 11 
CD11c+ DCs were extracted from spleens with magnetic beads and co-cultured with 12 
the indicated NKT hybridomas. Prior to co-culture 24.7 α-GC loaded and DN32.D3 13 
α-GC loaded were loaded with α-galactosylceramide for 4h. DCs from both young (2 14 
weeks) and adult Asm–/– mice were used as indicated. (h) CD11c+ DCs were extracted 15 
from spleens and incubated α-galactosylceramide for 4 or 24 hours and stained with 16 
an antibody recognizing α-galactosylceramide bound to CD1d in three technical 17 
replicates. The results are representative of two independent experiments. (i) DCs 18 
from WT and Asm–/– mice were loaded with ovalbumin and cultured with ovalbumin 19 
reactive T cells from OT-II mice. In all co-culture experiments (panels a, f, g and i) 20 
IL-2 levels were measured in three independent wells 20-24 hours after addition of 21 
the indicated NKT hybridomas, and all these results are representative of three 22 
independent experiments. In all panels the mean values are shown with the error bars 23 




except in panel h where 2-way ANOVA was used. *P<0.05, **P<0.01, ***P<0.001, 1 
***P<0.0001, NS not significant 2 
 3 
 4 
Figure 4. Human ASM deficiency is associated with reduced CD1d-restricted antigen 5 
presentation to iNKT cells and a reduced level of iNKT cells.  (a) EBV transformed 6 
B-cells were transduced with a lentiviral construct coding for human CD1d, loaded 7 
with α-galactosylceramide and cultured with the 58ab hybridoma. The graph shows 8 
the mean IL-2 levels from three independent wells with cells from the indicated 9 
individuals. The results are representative of three independent experiments. (b) 10 
Representative dot plots from a NPD patient and a healthy control. The percentages 11 
indicate the percentage of iNKT cells among lymphocytes. (c,d) The graphs 12 
demonstrate the level of iNKT (c) and T cells (d) in patients with NPD (n=5) 13 
compared to healthy controls (n=70). The percentages indicate the percentage of 14 
iNKT cells or T cells among lymphocytes. (e) ASM activity in PBMCs was measured 15 
using a colorimetric assay and the iNKT cell phenotype was examined by flow-16 
cytometry in healthy controls (n=25). The graphs show the correlation between ASM 17 
activity and the percentage of CD8 positive/CD161 positive cells among iNKT cells. 18 
In panel a the mean values are shown with the error bars representing the SEM. In 19 
panel c the line indicates the median value. P-values were calculated with 1-way 20 
ANOVA with Bonferroni’s method for multiple correction (panel a), the two-sided 21 
Mann-Whitney test (panel c and d), two-sided Pearson’s correlation (panel e) 22 





Figure 5. Lipids increased in Asm–/– mice block antigen presentation. (a) 1 
Sphingomyelin levels in the thymus of 2-week old Asm–/– (n=2) and WT (n=2) mice 2 
were quantified by mass spectrometry. The graphs show the mean levels of 3 
sphingomyelins and DH-sphingomyelins with carbon chains of different lengths. (b) 4 
Ceramide levels in the thymus of 2-week old Asm–/– (n=2) and WT (n=2) mice were 5 
quantified by mass spectrometry. The graphs show the mean levels of ceramides, DH-6 
ceramides, hexosylceramides and DH-hexosylceramides. (c, d) Plate-bound CD1d 7 
was incubated with α-galactosylceramide and a dose range of the indicated 8 
sphingomyelin species before addition of the iNKT hybridoma DN32.D3. The graphs 9 
demonstrate the mean level of IL-2 in three independent wells in the culture 10 
supernatants 16-24 hours after addition of iNKT cells. The stars indicate the 11 
significance levels compared with cytokine secretion when no sphingomyelin was 12 
added (0 nM). The results are representative of three independent experiments. In all 13 
panels the mean values are shown with the error bars representing the SEM. P-values 14 
were calculated with 1-way ANOVA with Bonferroni’s method for multiple 15 
correction. *P<0.001, **P<0.0001 16 
 17 
 18 
Figure 6. Lipids blocking CD1d-restricted antigen presentation are increased in 19 
thymic lysosomes of two week old Asm–/– mice. (a) Lysosomes were extracted from 20 
thymi of WT and Asm–/– mice using magnetic beads. The figure shows the lysosome 21 
identity for the samples by western blot with markers for different cellular 22 
compartments of the whole tissue lysate, the magnetic bead purified lysosomes, the 23 
soluble non-bound material, mitochondria enriched sediment and the non magnetic 24 




The blot images were cropped so all markers could be visualized together. (b) 1 
Electron microscopy images of the purified lysosome fraction. The red arrows 2 
indicate lysosomes. The black bar represents 100 nm. The results are representative of 3 
three independent experiments. (c) Sphingomyelin levels in the magnetic bead 4 
fraction were quantified by mass spectrometry. The graphs show the ratios of the 5 
indicated sphingomyelin species to the total level of ceramide in 2-week old WT and 6 
Asm–/– mice. (d,e) Ratios of the indicated sphingomyelin species to the total level of 7 
ceramide in 10 (panel d) and 18-20 (panel e) week old WT and Asm–/– mice. In all 8 
panels the mean values are shown with the error bars representing the SEM. P-values 9 
were calculated by two-sided t-test (c, d and e). *P<0.05, **P<0.01 ***P<0.001 10 
Lysosomal-associated membrane protein 1 (Lamp1), lysosome marker; Lysosomal-11 
associated membrane protein 2 (Lamp2), lysosome marker; Cytochrome c oxidase 12 
subunit 4 isoform 1 (Cox IV), mitochondria marker; Cathepsin D (CtsD), 35 kDa 13 
(mature) lysosomal marker, 55 kDa (immature) cytosol marker; Histone H3 (HisH3), 14 
nuclei marker; Ras-related protein Rab-5 (Rab5), early endosome marker; 15 




Figure 7. Mouse CD1d-sphingomyelin crystal structure. (a) Comparison using a lipid 20 
competition assay of the ability of sphingomyelin (top panel) and α-21 
galactosylceramide (middle panel) to outcompete sulfatide pre-loaded onto mCD1d, 22 
in a dose dependent manner, from equimolar ratio (1:1) to 9-fold molar excess of lipid 23 
compared to mCD1d-SLF complexes. Sulfatide has a single negative charge and 24 




sphingomyelin and α-galactosylceramide results in a gel shift to position 0. Pre-1 
loaded sphingomyelin can be outcompeted by sulfatide, but α-galactosylceramide 2 
forms a more stable interaction with CD1d and cannot be outcompeted in this in vitro 3 
assay (bottom panel). The results are representative of two independent experiments. 4 
(b) Mouse CD1d-sphingomyelin crystal structure overview of the CD1d (grey)-b2M 5 
(light blue) complex presenting sphingomyelin (yellow) between the a1 and a2 6 
helices. (c) 2FoFc electron density drawn as a blue mesh around the lipid and 7 
contoured at 1s. (d) H-bond interactions (blue dashed lines) of CD1d residues with 8 
sphingomyelin. (e) H-bond interactions (blue dashed lines) of CD1d residues with α-9 
galactosylceramide.  10 
 11 
 12 
Figure 8. Pharmacological ASM treatment in Asm–/– mice restores iNKT cells. (a-b) 13 
CD11c+ DCs were extracted from spleens of Asm–/– mice (a) or WT mice (b) treated 14 
with one dose of rhASM (5µg/g) 12-16 hour prior to extraction and loaded with α-15 
galactosylceramide for 4h. The indicated iNKT hybridomas were added and IL-2 16 
levels were measured in three independent wells after 20-24 hours. The results are 17 
representative of three independent experiments. (c) WT and Asm –/– mice were 18 
treated every other day from birth with rhASM (5µg/g). The graphs demonstrate the 19 
ASM activity levels in the liver and thymus of vehicle treated and rhASM treated 20 
Asm–/– and WT mice 2 days after the last enzyme injection. (d) The graphs 21 
demonstrate the levels of the blocking sphingomyelin species as measured by mass 22 
spectrometry after treatment with rhASM. (e) Representative dot-plot from the liver 23 
of a vehicle treated and a rhASM treated Asm–/– mouse. The cells are gated on the 24 




PBS57 tetramer positive cells. (f) iNKT cell levels at the age of 2 weeks in the 1 
thymus, spleen and liver of mice that were treated with rhASM or vehicle as indicated 2 
in the graphs. In panels c, d and f the numbers represent the pooled results from 3 3 
independent experiments with vehicle treated (Asm –/– (n=8) and WT (n=5)) and 4 
rhASM treated (Asm–/– (n=6) and WT (n=10)) mice. The hypothesis tested using the t-5 
test was that rhASM would increase iNKT cell abundance in Asm–/– mice. In all 6 
panels the mean values are shown with the error bars representing the SEM. P-values 7 
were calculated by two-sided t-test. *P<0.05, **P<0.01 ***P<0.001 8 
 9 
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Resolution (Å) 50-1.95 (2.00-1.95)*  
Rsym 11.9 (58.4)  
I / sI 23.4 (2.5)  
Completeness (%) 97.8 (82.5)  
Redundancy 4.2 (3.9)  
   
Refinement   
Resolution (Å) 50-1.95  
No. reflections 33,561  
Rwork / Rfree 22.3 / 25.6  
No. atoms 3,420  
    Protein 2,990  
    Ligand/ion 112  
    Water 318  
B-factors   
    Protein 33.4  
    Ligand/ion 51.1  
    Water 38.9  
R.m.s. deviations   
    Bond lengths (Å) 0.008  
    Bond angles (°) 1.11  
+ One crystal was used for data collection. *Values in parentheses are for highest-resolution shell. 4 
 5 














ONLINE METHODS 1 
Mouse models 2 
Asm–/– mice have been described earlier as a mouse model for Niemann-Pick 3 
disease14. These mice are on a C57BL/6 background and had been backcrossed for 4 
>10 generations. The mouse line was maintained by breeding heterozygote mice 5 
(Asm+/– x Asm+/–) since Asm–/– mice develop a neurological disease at an advanced 6 
age. The litters were genotyped by PCR (conditions available upon request). Mice 7 
used in the experiments were age and gender matched. Adult mice were defined as > 8 
6 weeks of age. wildtype littermates generated through the Asm+/– x Asm+/– breeding 9 
were used as controls. To generate bone-marrow chimeras wildtype bone marrow 10 
from C57BL/6 mice carrying CD45.1 that we were able to trace using flow-cytometry 11 
were utilized. In the experiments with mixed bone marrow chimeras, bone marrow 12 
from Ja18–/– mice was mixed at a 1:1 ratio with bone marrow from Asm–/– or wildtype 13 
mice. The CD45.1 (strain 2014) and Ja18–/– mice (strain 30524) models are 14 
commercially available through Jackson Laboratories (Bar Harbour, Maine, USA). 15 
OT-II mice (strain 4194) used to acquire ovalbumin reactive T cells are also 16 
commercially available through Jackson Laboratories. The number of mice included 17 
in each individual experiment was based on prior experience in the laboratory with 18 
similar experiments. No animals were excluded from the reported experiments. 19 
Animals were allocated to each experimental group based on genotype and 20 
age/gender without randomization and no blinding was performed. All mice were 21 
housed in a specific pathogen free facility with food and water ad libitum in 22 
accordance with the set forth by the Harvard Medical Area Standing Committee on 23 





Bone marrow chimeras  1 
Recipient mice were irradiated two times with 600 rad one day prior to injection of 2 
bone marrow. Bone marrow was extracted from donor mice from the femur by 3 
flushing with PBS, washing the cells and adjusting the concentration. For the mixed 4 
bone marrow chimeras, bone-marrow from Ja18–/– and Asm–/– or wildtype was mixed 5 
1:1. One million cells were injected through the tail vein. The mice were then kept on 6 
acidic water for 4 weeks and observed for general well being. After 3 months the 7 
engraftment and iNKT cell percentages were evaluated by flow cytometry. 8 
Engraftment was judged by CD45.1+ percentage among lymphocytes. 9 
 10 
a-GalCer hepatitis 11 
Age and gender matched mice were injected 2 µg a-GalCer i.p. Four hours after 12 
injection the mice were bled from tail vein, and 24 hours after the injection the mice 13 
were sacrificed and blood collected by cardiac puncture. IL-4 and IFN-γ were 14 
measured in the serum by ELISA (BD Biosciences, Franklin Lakes, New Jersey, 15 
USA). ALT was measured by a colorimetric assay (Stanbio, Boerne, Texas, USA). 16 
 17 
Concanavalin A hepatitis 18 
ConA (Sigma-Aldrich, St. Louis, Missouri, USA) was dissolved in PBS and injected 19 
through the tail vein at a dose of 13.5 mg/kg. Only male mice were used in these 20 
experiments. The mice were monitored hourly for well-being and blood sampled after 21 
6h. At 24h the mice were sacrificed and liver and blood were sampled. IL-4 and IFN-22 
γ were measured in the serum by ELISA (BD Biosciences). ALT was measured by a 23 
colorimetric assay (Stanbio). Liver sections were stained with hematoxylin and eosin 24 





Oxazolone skin painting and induced delayed type hypersensitivity  2 
At day 0 the abdominal skin of the mice was shaved. Then 150 µl 3% oxazolone 3 
dissolved in 3:1 ethanol:acetone was applied to the skin to sensitize the mice. The 4 
mice were followed daily with weight measurements. Five days after the skin 5 
sensitization the mice received a re-challenge by application of 20 µl 1% oxazolone 6 
dissolved in 1:1 acetone:sunflower oil to the ear. A sensitive micrometer was used to 7 
measure ear swelling the following days.  8 
 9 
Genotyping 10 
Mouse tails or mouse ear biopsies were digested in lysis buffer (100 mM Tris-HCl, 11 
pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl and proteinase K (Roche, Basel, 12 
Switzerland)) overnight at 55 C. Genomic DNA was phenol-extracted and 13 
isopropanol precipitated.  14 
 15 
Niemann Pick disease patients and healthy controls 16 
Five patients were analyzed using flow-cytometry of PBMCs, one NPD-A (1 year 17 
old) and four NPD-B patients (three adults and a 10 year old patient). In addition, 70 18 
control subjects were studied using flow-cytometry of PBMCs, 15 children and 55 19 
adults (blood donors). The children’s control group consisted of children undergoing 20 
orthopedic surgery, without infections, underlying chronic illness or taking 21 
medication. For correlation of iNKT phenotype and ASM activity blood samples from 22 
adult healthy controls were obtained from blood donors (from buffy coats) from the 23 
Blood Bank of Centro Hospitalar de São João, Porto, Portugal. The study was 24 




their legal representatives gave written consent to participate in the study. Blood 1 
samples were collected and processed within 24h after blood withdrew. PBMCs were 2 
isolated by density centrifugation before staining with fluorochrome conjugated 3 
antibodies or tetramers. The recruitment of NPD patients for generating lymphoblasts 4 
was approved by the institutional review board at the Icahn School of Medicine. 5 
Further details on the recruitment can be found in the Life Sciences Reporting 6 
Summary. 7 
 8 
Cell culture 9 
The murine NKT hybridomas 24.7, 24.8, 14.S6 and DN32.D3 were maintained in 10 
DMEM supplemented by 10% Fetal bovine serum (FBS), 100 units/mL of penicillin, 11 
100 µg/mL of streptomycin, and 0.25 µg/mL of amphotericin B (Antibiotic-12 
Antimycotic, Gibco®, Grand Island, New York, USA). Regular and transduced 13 
human EBV-transformed cells and the 58ab hybridoma were maintained in RPMI 14 
supplemented by 10% FBS, 100 units/mL of penicillin, 100 µg/mL of streptomycin, 15 
and 0.25 µg/mL of amphotericin B. Lentiviral transduction of EBV-transformed cells 16 
with a construct carrying human CD1D was performed as earlier described25.  17 
 18 
Immunomagnetic isolation of lysosomes 19 
The isolation of lysosomes from murine tissue was performed according to Fritsch et 20 
al. 47. In brief, tissue was thawed in 500 µl homogenization buffer (HB: 15 mM 21 
HEPES, pH7.4, 250 mM sucrose, 0.5 mM MgCl2 containing complete protease 22 
inhibitor and Cyanase nuclease (SERVA Electrophoresis GmbH, Heidelberg, 23 
Germany)) followed by 3 rounds of careful sonication (10 sec, amp 2.5 at 4 °C using 24 




volume of 1 ml, followed by centrifugation for 4 min at 1500 x g. The resulting 1 
supernatant was loaded on a 16% Iodixanol/HB cushion and centrifuged for 1 h at 2 
150k x g. The resulting floating fraction was aspirated carefully from the cushion and 3 
diluted to 750 µl with HB. 2 µg of anti-Lamp1 antibody (Santa Cruz Biotechnology, 4 
Dallas, USA, catalog number sc-8098) was added and incubated for 30 min rolling at 5 
4°C. 5 µl protein G microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany, 6 
catalog number #130-071-101) were added followed by another 30 min incubation. 7 
Samples were then loaded to a HOKImag magnetic isolation device (Hoock GmbH, 8 
Kiel, Germany) for organelle pulldown. The eluate was finally sedimented by 9 
centrifugation for 1 h at 20000 xg and used for downstream application. 10 
 11 
Lipidomics 12 
The sphingolipids were quantified by extracting them from the cells (after spiking 13 
with an internal standard cocktail from Avanti Polar Lipids, Alabaster, AL, Catalog 14 
#LM-6005) with analysis by liquid chromatography, electrospray-ionization tandem 15 
mass spectrometry using an API 4000 QTrap (SCIEX, Framingham, MA, USA) as 16 
previously described48. 17 
 18 
SDS-PAGE and Western blot 19 
For SDS-PAGE, sedimented organelles were resuspended in 15 µl modified RIPA 20 
buffer (50mM TRIS-HCl [pH 7.5], 150mM NaCl, 1% NP-40, 1% Triton X-100, 1mM 21 
EDTA, 0.25% Na-deoxycholate) and protein concentration was determined by BCA 22 
(Pierce, Waltham, MA, USA). For SDS-PAGE anyKD gels (Bio-Rad, Hercules, CA, 23 
USA) were used and 3 µg of protein were loaded. Proteins were transferred to PVDF 24 




skimmed milk in TBST and incubated over night with the primary antibody diluted 1 
1:500-1:5,000 in 5% skimmed milk. The peroxidase conjugated secondary antibodies 2 
were incubated for 1 h diluted 1:10,000 in 5% skimmed milk. Blots were developed 3 
using the ECL kit and films from GE Healthcare (Chicago, IL, USA). The following 4 
antibodies were used: anti-Lamp1 (Southern Biotech, Birmingham, AL, USA, catalog 5 
number 9835-01), anti-Lamp2 (Southern Biotech, catalog number 9840-01), anti-6 
CoxIV (Santa Cruz Biotechnology, catalog number sc-292052)  anti-HisH3 (Cell 7 
Signaling, Danvers, MA, USA, catalog number #4499S), anti-Rab5 (Santa Cruz 8 
Biotechnology, catalog number sc-598), anti-Cathepsin D (Millipore, Burlington, 9 
MA, USA, catalog number Ab2, IM16), anti-GAPDH (Proteintech, Rosemont, IL, 10 
USA, catalog number HRP-60004), anti-Tubulin (Proteintech, catalog number HRP-11 
66031). 12 
 13 
Electron microscopy 14 
EM was performed as described previously47. After sedimentation, isolated lysosomes 15 
were fixed in 3% glutaraldehyde/PBS, followed by overnight washing in 0.1 M 16 
phosphate buffer. Samples were dehydrated and then embedded in araldite. Ultrathin 17 
sections were treated with uranyl acetate and lead citrate. Images were acquired on 18 
a JEM1400plus (Jeol, Peabody, MA). 19 
 20 
Flow cytometry  21 
Lymphocyte populations from various murine organs were prepared as previously 22 
described49. In brief, the spleen and thymus were macerated to get a single cell 23 
population and passed through a filter and the liver retrogradely perfused through the 24 




suspended in 2% FBS in PBS. To avoid unspecific staining the Fc-receptors were 1 
blocked by using an anti-mouse CD16/32 antibody (clone 93, BioLegend, San Diego, 2 
USA, catalog number 101302) and stained with the appropriate fluorochrome 3 
conjugated monoclonal antibodies and a CD1d tetramer loaded with PBS57 (from the 4 
National Institute of Health tetramer core facility). The following antibodies were 5 
used for staining murine samples: anti-mouse CD3e (clone 145-2C11, BD 6 
Biosciences, catalog number 553066), anti-mouse TCRβ (clone H57-597, BD 7 
Biosciences, catalog number 553170), anti-mouse TCRβ (clone H57-597, BioLegend, 8 
catalog number 109212), anti-mouse CD45.1 (clone A20, BioLegend, catalog number 9 
110728), anti-mouse CD45.2 (clone 104, BD Biosciences, catalog number 553772), 10 
anti-mouse CD1d (clone 1B1, BD Biosciences, catalog number 553846), anti-mouse 11 
CD11c (clone HL3, BD Biosciences, catalog number 553801), anti-mouse TCRβ 12 
(clone H57-597, BioLegend, catalog number 109212), anti-mouse CD44 (clone 1M7, 13 
BioLegend, catalog number 103031), anti-mouse CD24 (clone M1/69, BioLegend, 14 
catalog number 101821), anti-mouse NK1.1 (clone PK136, BioLegend, catalog 15 
number 108724), anti-mouse CD3 (clone 145-2C11, BD Biosciences, catalog number 16 
553066), anti-mouse CD4 (clone RM4-5, BioLegend, catalog number 100528), anti-17 
mouse CD8 (clone 53-6.7, BioLegend, catalog number 100714), anti-mouse TCR g-d 18 
(clone UC7-13DS, BioLegend, catalog number 107504), anti-mouse CD304 (clone 19 
3E12, BioLegend, catalog number 145207), anti-mouse CD1d-aGalCer (clone L363, 20 
eBioscience, San Diego, CA, USA, catalog number 12-2019-82) and the murine 21 
CD1d tetramer loaded with PBS57 (from the National Institute of Health tetramer 22 
core facility). For evaluating CD1d expression on transduced EBV-lines anti-human 23 




acquired using a MACSQuant Analyser (Miltenyi Biotec) and a BD FACSVerseTM 1 
(BD Biosciences).  2 
For staining of the samples from Niemann-Pick disease patients and healthy controls 3 
the staining mixture was composed of anti-human CD3 (clone UCHT1, eBioscience, 4 
catalog number 17-0038-42), anti-human CD3 (clone SK7, eBioscience, catalog 5 
number 45-0036-42), anti-human CD4 (clone RPA-T4, eBioscience, catalog number 6 
25-0049-42), anti-human CD8 (clone RPA-T8, eBioscience, catalog number 47-0088-7 
42) and anti-human CD161 (clone HP-3G10, eBioscience, catalog number 53-1619-8 
42) antibodies and the human CD1d tetramer loaded with PBS57 (from the National 9 
Institute of Health tetramer core facility). Patient and control samples were acquired 10 
on a 3-laser BD FACS CantoTM II flow cytometer using BD FACSDivaTM software 11 
(BD Biosciences). Estimation of absolute cell counts was done using CountBright™ 12 
Absolute Counting Beads (Molecular Probes, Eugene, OR). The analyses were 13 
performed using the FlowJo software (Tree Star, Ashland, OR). 14 
 15 
Cell-based antigen-presentation assays 16 
DCs were extracted from the spleens of mice using CD11c selection beads (Miltenyi 17 
Biotec). Thymocytes were prepared by passing the thymus through a 40uM strainer 18 
followed by washing in PBS. 50k DCs or 100k thymocytes were seeded in 96 flat-19 
bottom cell-culture plates as indicated in the individual experiments. The cells were 20 
either loaded with 100 ng/ml a-GalCer or left untreated. Unloaded antigen was 21 
washed away before addition of 50-100k of the indicated NKT hybridomas. In some 22 
experiments the CD1d monoclonal antibody 19G11 (BioXCell, West Lebanon, NH, 23 
catalog number BE0000) or a corresponding isotype control (clone LTF-2, BioXCell, 24 




loaded with ovalbumin and cultured with 100k CD4 T cells from OT-II mice. 1 
Cytokine secretion was measured in the culture supernatants by ELISA (BD 2 
Biosciences). 3 
 4 
Surface loading of antigens 5 
DCs were extracted from spleens as described above followed by incubation with 100 6 
ng/ml a-GalCer. After incubation for 4 to 24 hours the cells were washed and stained 7 
with an anti-mouse α-GalCer:CD1d complex, clone L363 (eBioscience)50. Flow data 8 
was acquired as described under the section on flow-cytometry. 9 
 10 
Histological assessment of necrosis  11 
H&E stained liver sections were scanned using a Histech Panoramic Midi Slide 12 
Scanner (3DHISTECH, Budapest, Hungary). The resulting images were downscaled 13 
by a factor of 4. To get reliable segmentation of necrotic versus non-necrotic tissue, 14 
Ilastik 1.3.251, a toolkit for performing machine learning based image processing, was 15 
used. An average of 3 annotations were made for each segmentation class 16 
(background, necrotic- and normal tissue) on each of 5 cropped images that 17 
represented the overall variation of morphological phenotype among the samples. We 18 
employed all features of σ=10, and all colour- and texture-based features of σ=5. 19 
After training the random forest classifier, the entire sections of all samples were 20 
analyzed, and percentage of necrotic areas in each sample was determined.  21 
 22 
Enzyme replacement therapy 23 
Human recombinant ASM was produced as earlier described37, briefly, human ASM 24 




media. As iNKT cell development mainly takes place at an early age we started 1 
treatment as early as possible52. Neonatal mice from day two of life were injected 2 
5µg/g rhASM i.p. every other day until 2 weeks old. The mice were then sacrificed 3 
and the percentage of iNKT cells were determined by flow cytometry as described 4 
above. Samples from liver and thymus were also harvested at the same time for 5 
determination of ASM activity.  6 
 7 
Antigen presenting cell free antigen-presentation assays 8 
Monomeric mouse CD1d (NIH Tetramer Core Facility) was coated onto 96-well cell 9 
culture plates overnight (0.25 µg/well). Unbound CD1d was thoroughly washed away 10 
followed by incubation with 100 ng/ml of a-GalCer and a dose range of different 11 
sphingomyelin species for 16-24h. Unbound lipids were washed off and the 12 
a-GalCer reactive NKT hybridoma DN32.D3 was added. In the experiments 13 
evaluating a direct loading effect from rhASM a gradient of the same rhASM 14 
described above for the replacement experiments was added along with a gradient of 15 
bovine serum albumin as a negative control and Saposin-B (Cusabio, Houston, TX, 16 
USA) as a positive control11. These experiments were performed under neutral and 17 
acidic conditions. Cytokine secretion was measured in the culture supernatants by 18 
ELISA (BD Biosciences).  19 
 20 
Lipid competition assays 21 
Recombinant mouse CD1d was expressed and purified as previously reported53. 22 
CD1d was loaded with 3-times molar excess of sulfatides (bovine brain, Avanti Polar 23 
Lipids dissolved at 5 mg/ml in DMSO) in 100 mM Tris pH 7.0, 100 mM NaCl at 24 




Amicon filter cartridges (30 kDa molecular weight cut-off). CD1d-sulfatide 1 
complexes were then incubated overnight at room temperature with increasing 2 
concentration of either sphingomyelin (C24:1) or a-GalCer. Lipids were dissolved in 3 
DMSO (5 mg/ml) and incubated with CD1d in the presence of 0.01 % tyloxapol. As a 4 
control, CD1d-sulfatide complexes were incubated with tyloxapol only. In a reversed 5 
experiment, CD1d was first loaded with 6-times molar excess of either sphingomyelin 6 
(10 mg/ml in DMSO) or a-GalCer (0.2 mg/ml in vehicle) o/n at room temperature, 7 
purified from excess lipid by ultrafiltration and incubated with 3-times molar excess 8 
of sulfatide for 1h at 30˚C, which is the minimum dose and time necessary for full 9 
loading to insect cell expressed mCD1d (not shown). 4 µl (2-4 µg) of the various 10 
CD1d-lipid loading experiments were analyzed using native IEF gel electrophoreses 11 
using pH 5-8 gels on a PhastSystem (GE Healthcare) and stained with coomassie. 12 
 13 
CD1d-sphingomyelin crystallization and structure determination 14 
CD1d was loaded with sphingomyelin as reported above. Excess lipid was removed 15 
by size exclusion chromatography using a Superdex S200 GL10/300 (GE Healthcare). 16 
CD1d-SM complexes were concentrated to 5 mg/ml and crystals were grown by 17 
sitting drop vapor diffusion while mixing 0.5 µl protein with 0.5 µl precipitate (20 % 18 
polyethylene glycol 3350, 200 mM sodium malonate pH 7.0). Crystals were flash-19 
cooled in crystallization solution containing 20% glycerol. Diffraction data from a 20 
single crystal was collected at beamline 7.1 of the Stanford Synchrotron Lightsource. 21 
Diffraction data was processed to 1.95 Å using HKL2000 0.9854. Structure was 22 
determined using molecular replacement in Phaser55, followed by iterative cycles of 23 
model building in COOT 0.8.9.256 and restrained refinement in REFMAC 5.8.015857. 24 





ASM activity measurement  2 
For ASM activity measurement tissue samples were homogenized and subjected to 3 
three freeze/thaw cycles (at least 10 minutes frozen) followed by centrifugation. The 4 
protein in the supernatant was used for subsequent assays. Protein concentrations 5 
were measured and normalized using a bicinchoninic acid assay (Pierce). The ASM 6 
activity was then measured using an ASM Activity Assay Kit (Echelon Biosciences, 7 
Salt Lake City, UT) 8 
 9 
Statistical analyses 10 
All statistical analyses were carried out using Graphpad Prism 8.2 (GraphPad 11 
Software, San Diego, CA, USA). Variables were evaluated for a normal distribution 12 
either by the D'Agostino & Pearson normality test59 or by manually examining the 13 
distribution of observations. For normally distributed variables the two-sided 14 
Student’s T-test was used while for variables not fulfilling this requirement the two-15 
sided Mann-Whitney test was used. Correlations were evaluated by Pearson’s r. For 16 
experiments where multiple comparisons were included the 1-way ANOVA with 17 
Bonferroni’s method for multiple correction was used. For time-series a 2-way 18 
ANOVA test was used. A P-value < 0.05 was considered statistically significant. 19 
Further details on study design can be found in the Life Sciences Reporting Summary. 20 
 21 
Data availability 22 
The crystal structure is available at https://www.rcsb.org, PDB structure ID: 6CYW. 23 
The rest of the data that support the findings of this study are available from the 24 
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Supplementary Figure 1 
Examples of gating strategies for thymic samples. 
Thymocytes were prepared from the thymus and stained with monoclonal antibodies. The figure demonstrates representative dot plots 
and gating strategies for iNKT cells, iNKT cell stages, tetramer negative thymocytes and CD4/CD8 distribution. Other samples analyzed 




Supplementary Figure 2 
Acid sphingomyelinase deficient mice have reduced numbers of iNKT cells with an altered CD4/CD8 distribution. 
Lymphocytes were prepared from the tissues indicated in the figure followed by staining with monoclonal antibodies and a CD1d tetramer. 
(a) Representative flow cytometry dot plots of lymphocytes from WT and Asm–/– mice visualizing the number of iNKT cells in thymus and 
liver as defined by a PBS57-loaded CD1d tetramer and CD3. The results are representative of three independent experiments. (b) 
Distribution of CD4 and CD8 expression among iNKT cells from Asm–/–(n=5) and WT (n=5) mice. The results are representative of two 
independent experiments. In all panels the mean values are shown with the error bars representing the SEM. P-values were calculated 







Supplementary Figure 3 
T cell distribution, CD4/CD8 expression, T regulatory cells and gd T cells in Asm–/– compared to wildtype mice   
Lymphocytes were prepared from the indicated tissues from Asm–/– (n=5) and WT (n=5) mice and stained with monoclonal antibodies. 
(a) The percentages indicate CD3 positive cells among PBS57-CD1d tetramer negative lymphocytes. The results are representative of 
two independent experiments. (b) The percentages indicate the distribution of CD4 and CD8 expression among PBS57-CD1d tetramer 
negative thymocytes (for thymus) and PBS57-CD1d tetramer negative T cells (for spleen and liver). The results are representative of two 
independent experiments. (c) The percentages indicate the percentage of T regulatory cells or gd T cells among T cells or lymphocytes 
excluding iNKT cells. The results are representative of two independent experiments. In all panels the mean values are shown with the 
error bars representing the SEM. P-values were calculated by two-sided t-test. *P<0.05, **P<0.01, SP single positive; DN double negative; 






Supplementary Figure 4 
CD1d expression in thymocytes and CD11c+ DCs from Asm–/– and wildtype mice.  
Thymocytes were prepared by manual maceration through a mesh and thereafter stained with a monoclonal antibody against CD1d. 
CD11c+ DCs were extracted from spleens with CD11c magnetic beads and stained with a monoclonal antibody against CD1d. The two 
top histograms demonstrate the CD1d levels in thymocytes from young (left) and adult (right) mice. The two lower histograms demonstrate 
the CD1d levels in DCs from young (left) and adult (right) mice. The results are representative of three independent experiments. MFI 




Supplementary Figure 5 
Activation of NKT cells by thymocytes and DCs is blocked by a CD1d antibody and bone-marrow transplantation in Asm–/– and 
wildtype mice. 
(a) Thymocytes were prepared by manual maceration through a mesh and loaded with α-GalCer for 4 hours (for 24.7 and DN32.D3 α-
GC loaded) or left untreated (for 24.7 endogenous) followed by culture with the indicated NKT hybridomas for 16-24h. Cytokine levels 
were measured in the culture supernatants from three independent wells. The results are representative of two independent experiments. 
(b) Bone-marrow transplantation in Asm–/– (n=5) and WT mice (n=3). Bone-marrow chimeras were made by irradiating Asm–/– and WT 
mice followed by injection of donor bone-marrow from Asm–/– or WT mice. 3 months later the mice were sacrificed followed by flow-
cytometry of tissue samples. The graphs demonstrate the percentage of CD1d-PBS57 tetramer positive cells among TCR-β positive cells 
(iNKT cells) from the indicated tissues. (c) CD11c+ DCs were extracted from spleens with CD11c magnetic beads and loaded with α-
GalCer for 4 hours (upper panel) or left untreated (lower panel) followed by co-culture with the indicated NKT hybridomas for 16-24h. 
Cytokine levels were measured in the culture supernatants from three independent wells. The results are representative of two 
independent experiments. In all panels the mean values are shown with the error bars representing the SEM. P-values were calculated 




Supplementary Figure 6 
Transduction efficacy in transduced EBV transformed B-cells and Phenotype of iNKT cells and T cells in Niemann-Pick disease 
patients compared to controls. 
(a) EBV transformed B-cells from three healthy controls and one Niemann-Pick disease (NPD) patient were lentivirally transduced with a 
construct encoding human CD1d. The cells were thereafter subjected to FACS sorting. The histograms indicate the CD1d expression in 
the transduced and sorted cells (red lines) compared with the corresponding untransduced cells (black line). (b,c) Phenotype of iNKT 
cells and T cells in NPD patients compared to controls. Lymphocytes from five NPD patients (four type B and one type A) and 70 healthy 
controls were investigated with flow-cytometry. (b) CD4, CD8, double negative (DN) and CD161 distribution in iNKT cells. (c) CD4 and 
CD8 distribution in T cells. The line indicates the median. A two-sided Mann-Whitney test was used for significance testing. *P<0.05, 




Supplementary Figure 7 
Lipidomics results from liver samples from 2 week old Asm–/– and wildtype mice. 
Sphingomyelin and ceramide levels in the liver of 2 week old Asm–/– (n=2) and wildtype (n=2) mice were quantified by mass spectrometry. 
(a) The graphs show the mean levels of sphingomyelins and DH-sphingomyelins with carbon chains of different lengths. (b) The graphs 





Supplementary Figure 8 
Sphingomyelin does not affect direct activation of iNKT cells and acid sphingomyelinase does not directly affect loading of 
lipid antigens.   
(a) Cell-culture plates were first coated with CD3 followed by incubation with the indicated concentrations of sphingomyelin 24:1. After 
thorough washing the DN32.D3 hybridoma was added and incubated for 16 hours. IL-2 levels in the supernatant were determined by 
ELISA. The results are representative of two independent experiments. (b) Murine CD1d was coated on cell-culture plates followed by 
incubation with α-GalCer and Saposin-B, rhASM or BSA in the indicated concentrations overnight. Thereafter, the DN32.D3 hybridoma 
was added for 16 hours. IL-2 levels in the supernatant were determined by ELISA. The left panel shows the results when the experiment 
was performed under acidic conditions while the right panel show the results under neutral conditions. The results are representative of 
two independent experiments. In all panels the mean values are shown with the error bars representing the SEM. 
	
Patient number Disease Sex Age (years) 
Sphingomyelinase activity in 
patient fibroblasts * 
1 NPD A M 1 not available 
2 NPD B M 41 not available 
3 NPD B M 54 2.06 nmol/h/mg 
4 NPD B F 10 0.2 nmol/h/mg 
5 NPD B F 41 not available 
	
	
Suppl. Table 1. Clinical information on NPD patients analyzed for NKT-cells.  
*reference values for control subjects between 84 and 285 
	
	
